|View printer-friendly version|
Cidara Therapeutics Announces Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting
Presentations Will Highlight Data from Studies of Novel Echinocandin CD101 and Reinforce the Unmet Need for Effective New VVC Treatments
The IDSOG Scientific Program Committee selected Cidara’s abstracts for one oral and two poster presentations at the meeting. The presentations will highlight attributes of the company’s lead antifungal drug candidate CD101 topical as a potential treatment for VVC, and report on new research investigating the unmet needs in VVC treatment based on patient-reported measures.
“Our presence at this year’s IDSOG meeting underscores the importance
that we and the broader scientific community place on advancing CD101
topical as the first echinocandin antifungal being studied in VVC,” said
Details for the Cidara IDSOG 2016 presentations are as follows:
Time-Kill Kinetics of the Novel Echinocandin CD101 for
Azole-Susceptible and -Resistant Candida spp. at pH 4 in
Vagina-Simulative Medium; J.
Locke, et. al.
- This study investigated the killing kinetics of CD101 against Candida spp., including azole-S and -R strains, in conditions and at concentrations relevant to topical treatment of VVC.
CD101 Gel Formulation is Highly Efficacious Against Azole-Resistant C.
albicans in a Rat Model of VVC; V. Ong, et. al.
- This study evaluated the efficacy of the gel formulation of CD101 compared to marketed miconazole and nystatin creams and oral fluconazole in an immunosuppressed rat model of VVC.
Characterizing Women in the U.S. with Acute and Recurrent Vulvovaginal
Candidiasis and their Unmet Needs; P. Daruwala, et. al.
- This poster will summarize results from an online survey of 478 women in the U.S. with either recurrent VVC, mild acute VVC or moderate to severe acute VVC. The survey was designed to identify differences in characteristics and attitudes related to VVC treatment and unmet needs in the current treatment paradigm.
Copies of these presentations and posters will be available on the Cidara website following the IDSOG 2016 meeting: http://www.Cidara.com/
About CD101 Topical
CD101 topical is the first topical agent in the echinocandin class of
antifungals and exhibits a broad spectrum of fungicidal activity against Candida
Cidara is a clinical-stage biotechnology company focused on the
discovery, development and commercialization of novel anti-infectives
for the treatment of diseases that are inadequately addressed by current
standard-of-care therapies. Cidara's initial product portfolio comprises
two formulations of the company's novel echinocandin, CD101. CD101 IV is
being developed as a once-weekly, high-exposure therapy for the
treatment and prevention of serious, invasive fungal infections. CD101
topical is being developed for the treatment and prevention of
vulvovaginal candidiasis (VVC), a prevalent mucosal infection. In
addition, Cidara has developed a proprietary immunotherapy platform,
Cloudbreak™, designed to create compounds that direct a patient's immune
cells to attack and eliminate pathogens that cause infectious disease.
Cidara is headquartered in
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effectiveness, safety, long-acting nature,
anticipated human dosing and other attributes of CD101 IV and CD101
topical, and their potential to treat infections, as well as the
intended design of current and future Cloudbreak compounds. Risks that
contribute to the uncertain nature of the forward-looking statements
include: the success and timing of Cidara’s preclinical studies and
clinical trials; regulatory developments in